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olycemic control has been a key target of therapy for
atients with diabetes. In addition to the control of symp-
oms, it has been proposed that the potential reduction of
dditional morbidity and mortality represented another
ationale for glycemic control. It has been assumed that
hysiologic perturbations associated with inadequate meta-
olic glucose control would be improved by restoration of
ormalized metabolism. In patients with type 1 (insuli-
openic) diabetes mellitus, studies have indeed demon-
trated significant microvascular (but less macrovascular)
enefit when euglycemia as measured by glycosylated he-
oglobin A1c (HbA1c) is approached with multiple daily
nsulin injections (1,2).
See page 422
Insulin resistance resulting in impaired glucose handling
metabolic syndrome, type 2 diabetes) has become an
ncreasing worldwide problem that has not been resolved in
he 5 decades since the first sulfonylurea was developed.
arly efforts in the type 2 diabetic patient to restore normal
lycemia were hampered by the lack of efficacy of early oral
edications. Although a heavily promoted plethora of
ewer and more potent agents have become available, the
ifference between the mortality/morbidity rates of type 2
iabetic and nondiabetic patients has not been narrowed.
ome small studies have suggested that tight insulin control
f glycemia benefited these patients in the short term,
roadening the interest in glucose control in intensive care
nits after myocardial infarction (3), in critical illness, and
mong guideline writers (4). The anticipation that reduction
f morbidity or mortality by installation of a insulin/
lycemic pump or nomogram replacing the sliding scale has
een countered by the reality of evidence to the contrary (5).
ikewise, more intensive regimens of oral agents to improve
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Joslin Diabetes Center and Mt. Auburn Hospital, Boston and Cam-b
ridge, Massachusetts; and the Cardiovascular Divisions, Brigham and Women’s
ospital, Harvard Medical School, Boston, Massachusetts.ortality and morbidity from macrovascular disease in type
diabetes have shown mixed results (6–10).
Guidelines have been written recommending how best to
ive the diabetic patient “quality care.” But these diabetes
uidelines were not developed for heart failure patients who
equire numerous medications for that diagnosis, often have
oncomitantly decreased renal function, and may have a
arrower therapeutic window for optimizing outcomes. The
nderlying hypothesis that there may be a benefit to tight
lycemic control in this population requires testing.
Patients with both heart failure and diabetes are often
nrolled in an intensive disease-management program.
iven the cost of treating patients with the combination of
eart failure and diabetes, it is imperative to delineate the
mpact of strategies that can be used to decrease mortality,
orbidity, and overall cost. Recognizing this problem,
guilar et al. (11) report in this issue of the Journal the
-year follow-up data from a retrospective observational
atabase of 5,815 predominantly obese males with heart
ailure and diabetes treated in ambulatory clinics at Veterans
ffairs medical clinics. Other than sex, they represented the
ypical heart failure patient with a mean age of 69 years and
ody mass index of 31.7 kg/m2. Approximately one-half of
he patients had reasonably preserved left ventricular func-
ion (ejection fraction 40%). The patients were stratified
nto quintiles based upon their HbA1c. After adjusting for
linical characteristics, the data demonstrated a U-shaped
urve, with the quintiles at the lowest and highest HbA1c
evels exhibiting the highest mortality.
Patients with the lowest HbA1c levels manifested clinical
haracteristics that were both favorable and unfavorable.
hese patients seemingly had fewer complications from
heir diabetes with less intensive treatment required. In
ddition, a higher proportion had a preserved or near-
ormal ejection fraction, less peripheral arterial disease, and
here were fewer hospitalizations for heart failure within the
rior 2 years. These favorable characteristics were counter-
alanced by patients in this lowest quintile (6.4%) being
lder and having a lower glomerular filtration rate (GFR),
ore anemia, greater prevalence of chronic obstructive
ulmonary disease, a bit more cancer, and less use of statins
r angiotensin-converting enzymes/angiotensin receptor
lockers). Interestingly, the lowest quintile HbA1c group
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Glycemia, HF, and Type 2 Diabetes July 28, 2009:429–31atients were more likely to be solely on a sulfonylurea to
ontrol glycemia and were less likely to receive a biguanide,
hiazolidinedione, or insulin. The lowest quintile group
ctually had similar GFR, hemoglobin, lipid profile, ejection
raction, and prior hospitalization history to the quintile
hat exhibited the lowest mortality (those with glycohemo-
lobin 7.2). Thus, the most striking difference between
he lowest HbA1c quintile group that was at highest risk
nd the mid HbA1c quintile group with the lowest mortal-
ty appeared to be the “baseline” glycohemoglobin. In the
roup with the lowest quintile of glycohemoglobin, we are
ikely seeing the “real-world” risk of unawareness of spon-
aneous or iatrogenic hypoglycemia in the cardiac popula-
ion (12).
Patients in the highest HbA1c quintile (glycohemoglobin
9.0) were younger with more aggressive (complicated)
iabetes, peripheral vascular disease, higher lipids and insu-
in, as well as biguanide use. The higher mortality in this
roup is thus not unexpected.
There are some limitations of the study that deserve
estating. As this is a Veterans Affairs study, women are
nderrepresented. In most such studies, women are a bit
lder than men, have lower GFR, more preserved ejection
raction heart failure, and more anemia. In this they would
eem to represent the lowest HbA1c quintile and be more at
isk for cardiovascular events. None of the studies of which
e are aware suggests that tight control of glycemia benefits
omen more than men. Interpretation of the relationship
etween glycohemoglobin and mortality is limited by a lack
f information on the underlying causes of the death. It
ould reasonable to suspect, however, that the contribution
f hypoglycemia to morbidity and mortality may have been
igher in the quintile with the lowest glycohemoglobin,
specially because a higher percentage of patients was taking
edications known to cause such events (12). Among the
nstated limitations in most such studies is that during the
-year follow-up, new drugs will have become available and
hanged the profile of current patient care. Indeed, the
harmaceutical marketplace has seen the addition of many
ore agents aimed at the control of diabetes mellitus since
002. Unfortunately, none of these agents (incretins or
nhibitors of inappropriate glucagon secretion) has been
ested in the crucible of a health outcome trial. Until they
re, we must understand that our attempts at “normaliza-
ion” of impaired glucose metabolism as manifested by a
arker such as HbA1c fall far short of the goal of elimi-
ating the excess of cardiovascular risk suffered by the
iabetic population.
Several reasonable explanations exist for the findings of
his study. Unmeasured factors associated with low HbA1c
ay exist that increase the risk of mortality in these patients.
he therapies used varied in the different groups, and the
xcess risk may be a reflection of these variations. Moreover,
oncomitant kidney disease in patients using sulfonylureas
ould increase risk for patients receiving this single agent.
ther comorbid illnesses, including subclinical right ven-ricular dysfunction with hepatic or renal impairment may
lter the safety of some of these agents, promoting episodic
ypoglycemia and increased catechol states. Symptoms of
ypoglycemia in these patients may be masked by the
ustomary use of beta-blockers and by symptoms of heart
ailure such as fatigue and dizziness. Certainly it would be
mportant to distinguish whether it was the level of HbA1c
r the response of the patient to the medications adminis-
ered that relates most closely to the outcomes observed.
his deserves some discussion, as it is the higher mortality
hen glucose is “controlled better” and with less medicine
hat is the unexpected finding.
We have always assumed that restoration of euglycemia
ould eliminate some of the excess morbidity and mortality
f diabetes. The current findings that this is not so are
oncordant with other studies, including the ACCORD
Action to Control Cardiovascular Risk in Diabetes) study,
hich demonstrated that very tight control of glucose in
atients with diabetes (with or without episodes of hypo-
lycemia) may not improve mortality, and may, in fact,
ncrease it (13). This observational data adds support to the
rowing concern that we may need to redefine the optimal
bA1c level in various patient populations, including heart
ailure. As we move forward in optimizing care for patients
ith heart failure and diabetes, we need a shift in the targets
f therapy. Clearly the outcomes of cardiovascular morbidity
nd mortality should be standard measures of efficacy for
ovel diabetes therapies. Glycemic control as measured by
lycohemoglobin or nonspecific advanced glycated end prod-
cts may not adequately reflect the elements of diabetes that
ead to an excess in mortality or decreased microvascular
lood flow. Neither may specific glycated end products such
s carboxymethyl and carboxyethyl lysine, which are cur-
ently under investigation for discrimination of protective/
njurious properties in the genesis of diabetic complications
14). Recognizing the fallibility of current markers and study
ubsets, these targets may require modification. We must
uestion in such patients whether current concepts of meta-
olic control do more harm than good. In the 70-year-old
eart failure patient with diabetes, this study suggests that there
s little benefit to a glycohemoglobin level below 7.1%.
eprint requests and correspondence: Dr. Larry A. Weinrauch,
21 Mount Auburn Street, Watertown, Massachusetts 02472.
-mail: lweinrauch@hms.harvard.edu.
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